Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Upgraded by StockNews.com

Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Thursday.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday. Barclays lifted their target price on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday.

Sangamo Therapeutics Stock Performance

NASDAQ:SGMO traded down $0.29 during midday trading on Thursday, reaching $2.15. 7,610,567 shares of the stock traded hands, compared to its average volume of 6,930,090. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The business has a 50-day moving average of $1.30 and a two-hundred day moving average of $0.85. The stock has a market capitalization of $447.68 million, a PE ratio of -2.87 and a beta of 1.10.

Institutional Trading of Sangamo Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SGMO. Renaissance Technologies LLC raised its stake in shares of Sangamo Therapeutics by 58.8% during the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after buying an additional 1,528,600 shares during the period. Acadian Asset Management LLC lifted its stake in Sangamo Therapeutics by 4.0% during the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock worth $3,311,000 after acquiring an additional 192,385 shares in the last quarter. Marshall Wace LLP lifted its stake in Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 207,476 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System raised its position in Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 23,650 shares in the last quarter. 56.93% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.